Avisa Diagnostics Inc. (FOGCF)
Avisa Diagnostics Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Santa Fe, NM, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $97,176. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -257.6%. Its beta of 1.28 implies it has historically moved more than the broad market.
Avisa Diagnostics Inc., a clinical-stage medical device company based in Santa Fe, New Mexico, is dedicated to developing the Avisa BreathTest. This innovative drug/device biomarker technology platform is designed for the ultra-rapid identification of virulent bacterial pathogens and the subsequent monitoring of bacterial load. The system works by analyzing a patient's breath after they have inhaled or ingested Avisa's proprietary drug substrates. The company has already established clinical proof-of-concept through trials in conditions such as cystic fibrosis, tuberculosis, and community-acquired pneumonia, and is now concentrating on pivotal trials for Post-COVID-19 bronchiectasis and ventilator-associated pneumonia.
Avisa Diagnostics Inc. is most often compared with the following Healthcare names: